Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00847886 · ClinicalTrials.gov registry record · Phase 1

Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis

A Phase 1 study of Rheumatoid Arthritis, sponsored by Lexicon Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target
1
Study location

NCT00847886 is a Phase 1 study of Rheumatoid Arthritis that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 15 participants, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00847886, a Phase 1 study of Rheumatoid Arthritis, has completed, sponsored by Lexicon Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to evaluate the effect of LX3305 on methotrexate (MTX) pharmacokinetics and to evaluate the safety and tolerability of LX3305 given over 14 days in subjects with stable rheumatoid arthritis that are receiving stable doses of MTX.

Conditions Studied

Interventions

  • DRUG Methotrexate
  • DRUG LX3305
  • DRUG LX3305 Placebo

Study Locations (1)

Texas

  • Metroplex Clinical Research Center - Dallas

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2009-02
Est. Completion 2009-03
Phase Phase 1

Sponsor

Lexicon Pharmaceuticals

56 total trials

What the Registry Record Tells You About NCT00847886

The ClinicalTrials.gov registry entry for NCT00847886 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower). The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 3 interventions - of which Methotrexate is the first listed.

NCT00847886 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00847886 about?

NCT00847886 is a clinical study titled "Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis". The purpose of the study is to evaluate the effect of LX3305 on methotrexate (MTX) pharmacokinetics and to evaluate the safety and tolerability of LX3305 given over 14 days in subjects with stable rheumatoid arthritis that are receiving stable doses of MTX.

What is the current status of trial NCT00847886?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2009-02. Estimated completion is 2009-03.

What conditions does trial NCT00847886 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT00847886?

The interventions under investigation include: Methotrexate (DRUG), LX3305 (DRUG), LX3305 Placebo (DRUG).

Who is sponsoring clinical trial NCT00847886?

This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00847886 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.